Equities analysts forecast that Henry Schein, Inc. (NASDAQ:HSIC) will report sales of $2.48 billion for the current fiscal quarter, according to Zacks Investment Research. Eight analysts have made estimates for Henry Schein’s earnings. The lowest sales estimate is $2.45 billion and the highest is $2.51 billion. Henry Schein reported sales of $3.33 billion in the same quarter last year, which would suggest a negative year-over-year growth rate of 25.5%. The company is scheduled to announce its next earnings report on Monday, August 5th.

On average, analysts expect that Henry Schein will report full-year sales of $10.00 billion for the current year, with estimates ranging from $9.92 billion to $10.17 billion. For the next year, analysts forecast that the company will report sales of $10.38 billion, with estimates ranging from $10.21 billion to $10.72 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Henry Schein.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings data on Tuesday, May 7th. The company reported $0.80 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.04. The firm had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.36 billion. Henry Schein had a return on equity of 18.35% and a net margin of 4.10%. The company’s quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.95 earnings per share.

Several research firms have recently commented on HSIC. Zacks Investment Research downgraded Henry Schein from a “hold” rating to a “sell” rating in a report on Wednesday, February 6th. BidaskClub upgraded Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, February 7th. UBS Group began coverage on Henry Schein in a report on Thursday, January 17th. They set a “sell” rating and a $73.00 price objective for the company. ValuEngine upgraded Henry Schein from a “sell” rating to a “hold” rating in a report on Monday, February 4th. Finally, Barrington Research upped their price target on Henry Schein from $72.00 to $75.00 and gave the stock an “outperform” rating in a report on Wednesday, May 8th. Six research analysts have rated the stock with a sell rating, nine have given a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $74.27.

In related news, Director Philip A. Laskawy sold 1,084 shares of the company’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $59.86, for a total transaction of $64,888.24. Following the completion of the sale, the director now owns 32,899 shares in the company, valued at $1,969,334.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.06% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Financial Gravity Companies Inc. purchased a new position in Henry Schein in the fourth quarter worth $29,000. CSat Investment Advisory L.P. boosted its position in Henry Schein by 115.6% in the first quarter. CSat Investment Advisory L.P. now owns 552 shares of the company’s stock worth $33,000 after purchasing an additional 296 shares during the last quarter. Parallel Advisors LLC boosted its position in Henry Schein by 67.4% in the first quarter. Parallel Advisors LLC now owns 586 shares of the company’s stock worth $35,000 after purchasing an additional 236 shares during the last quarter. Bruderman Asset Management LLC purchased a new position in Henry Schein in the fourth quarter worth $39,000. Finally, First Hawaiian Bank boosted its position in Henry Schein by 66.7% in the first quarter. First Hawaiian Bank now owns 650 shares of the company’s stock worth $39,000 after purchasing an additional 260 shares during the last quarter.

NASDAQ HSIC opened at $66.58 on Thursday. The company has a market cap of $9.98 billion, a PE ratio of 16.12, a PEG ratio of 2.40 and a beta of 0.89. Henry Schein has a 52 week low of $56.58 and a 52 week high of $91.35. The company has a quick ratio of 0.93, a current ratio of 1.65 and a debt-to-equity ratio of 0.34.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Recommended Story: Net Income

Get a free copy of the Zacks research report on Henry Schein (HSIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.